Experimental cancer drug NC525 fails to advance in early trial
Disease control
Terminated
This early-phase study tested a new drug called NC525 in 28 adults with advanced blood cancers (acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndrome) that had come back or not responded to treatment. The main goal was to check the drug's safety and…
Phase: PHASE1 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC